Title |
BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
|
---|---|
Published in |
BMC Cancer, July 2014
|
DOI | 10.1186/1471-2407-14-503 |
Pubmed ID | |
Authors |
Mauricette Michallet, Elisabeth Luporsi, Pierre Soubeyran, Nadia Ali Amar, Vincent Boulanger, Miguel Carreiro, Louis-Marie Dourthe, Jean-Luc Labourey, Daniel Lepille, Frédéric Maloisel, Jean-Loup Mouysset, Sophie Nahon, Bérengère Narciso, Pierre Nouyrigat, Raouf Radji, Nacéra Sakek, Hélène Albrand |
Abstract |
The approval of epoetin biosimilars in the European Union requires extensive scientific evaluation and stringent regulatory procedures, including post-marketing studies. The ORHEO (place of biOsimilaRs in the therapeutic management of anaemia secondary to chemotherapy in HaEmatology and Oncology) study was an observational, longitudinal, multicentre study performed in France to evaluate the efficacy and safety of biosimilar epoetins for the treatment of chemotherapy-induced anaemia (CIA) in the clinical setting. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 1 | 50% |
Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Hungary | 1 | 3% |
Brazil | 1 | 3% |
Unknown | 36 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 21% |
Other | 6 | 16% |
Student > Bachelor | 4 | 11% |
Student > Ph. D. Student | 4 | 11% |
Researcher | 3 | 8% |
Other | 7 | 18% |
Unknown | 6 | 16% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 45% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 16% |
Agricultural and Biological Sciences | 3 | 8% |
Biochemistry, Genetics and Molecular Biology | 2 | 5% |
Business, Management and Accounting | 1 | 3% |
Other | 2 | 5% |
Unknown | 7 | 18% |